Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.
[CONTEXT] Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome.
- p-value P < .001
- 95% CI 1.22-1.51
- 추적기간 5.2 years
- 연구 설계 cohort study
APA
Kwon H, Han KD, et al. (2024). Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.. The Journal of clinical endocrinology and metabolism, 109(3), e1095-e1104. https://doi.org/10.1210/clinem/dgad575
MLA
Kwon H, et al.. "Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.." The Journal of clinical endocrinology and metabolism, vol. 109, no. 3, 2024, pp. e1095-e1104.
PMID
37921093
Abstract
[CONTEXT] Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. Obesity and metabolic syndrome are known risk factors for thyroid cancer.
[OBJECTIVE] We investigated the association between NAFLD and thyroid cancer risk in young adults.
[METHODS] This nationwide cohort study included 1 135 967 participants aged 20 to 39 years who underwent 4 consecutive health screenings in South Korea. NAFLD was categorized using the fatty liver index (FLI), as follows: ≥60, 30 to 60, and <30. The cumulative FLI points were defined as the number of times participants had a FLI of ≥30 (0-4).
[RESULTS] During a median follow-up of 5.2 years, 4126 participants (0.36%) were newly diagnosed with thyroid cancer. Compared with the participants with an FLI of <30, those with an FLI of 30 to 60 (men: hazard ratio [HR] 1.36 [95% CI, 1.22-1.51] and women: HR 1.44 [1.21-1.70]) and those with an FLI of ≥60 (men: HR 1.71 [1.53-1.92] and women: HR 1.81 [1.46-2.25]) had a significantly higher risk of thyroid cancer. Participants with higher cumulative FLI points had a higher risk of thyroid cancer compared to those with a cumulative FLI point of 0 (P < .001). During the follow-up period, the participants with an increased FLI exhibited an increased risk of thyroid cancer.
[CONCLUSION] NAFLD was associated with an increased risk of thyroid cancer in young adults. Repeatedly elevated FLI and progression of NAFLD were associated with an increased risk of thyroid cancer in this study.
[OBJECTIVE] We investigated the association between NAFLD and thyroid cancer risk in young adults.
[METHODS] This nationwide cohort study included 1 135 967 participants aged 20 to 39 years who underwent 4 consecutive health screenings in South Korea. NAFLD was categorized using the fatty liver index (FLI), as follows: ≥60, 30 to 60, and <30. The cumulative FLI points were defined as the number of times participants had a FLI of ≥30 (0-4).
[RESULTS] During a median follow-up of 5.2 years, 4126 participants (0.36%) were newly diagnosed with thyroid cancer. Compared with the participants with an FLI of <30, those with an FLI of 30 to 60 (men: hazard ratio [HR] 1.36 [95% CI, 1.22-1.51] and women: HR 1.44 [1.21-1.70]) and those with an FLI of ≥60 (men: HR 1.71 [1.53-1.92] and women: HR 1.81 [1.46-2.25]) had a significantly higher risk of thyroid cancer. Participants with higher cumulative FLI points had a higher risk of thyroid cancer compared to those with a cumulative FLI point of 0 (P < .001). During the follow-up period, the participants with an increased FLI exhibited an increased risk of thyroid cancer.
[CONCLUSION] NAFLD was associated with an increased risk of thyroid cancer in young adults. Repeatedly elevated FLI and progression of NAFLD were associated with an increased risk of thyroid cancer in this study.
MeSH Terms
Male; Humans; Female; Young Adult; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Cohort Studies; Risk Factors; Thyroid Neoplasms
같은 제1저자의 인용 많은 논문 (5)
- A pH-Sensitive Sprayable Fluorescent Probe Enables Accurate Visualization of Thyroid Cancer Margins for Fluorescence-Guided Surgery in Orthotopic Mouse Models.
- Artificial intelligence-assisted breast ultrasound: modest AUROC improvement and shorter interpretation time without significant change in diagnostic accuracy.
- Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.
- Impact of microscopic margin involvement on recurrence of papillary thyroid carcinoma.
- Customized Reconstruction of Lower Eyelid Defects.